Leukostasis and hyperleukocytosis: Difference between revisions
Neil.m.young (talk | contribs) (Text replacement - " ==" to "==") |
ClaireLewis (talk | contribs) |
||
(7 intermediate revisions by 5 users not shown) | |||
Line 1: | Line 1: | ||
==Background== | ==Background== | ||
*Hyperleukocytosis is lab abnormality of WBC >50-100K | *Hyperleukocytosis is lab abnormality of WBC >50-100K | ||
*Blood viscosity increases | |||
*Leukostasis is symptomatic hyperleukocytosis; it is a medical emergency | *Leukostasis is symptomatic hyperleukocytosis; it is a medical emergency | ||
**Most commonly seen with [[AML]] or [[CML]] in | **Most commonly seen with [[AML]] or [[CML]] in blast crisis | ||
**High blast cell count > WBC plugs in microvasculature | **High blast cell count > WBC plugs in microvasculature | ||
***Brain and lung are most commonly affected | ***Brain and lung are most commonly affected | ||
Line 36: | Line 37: | ||
**[[DIC]] occurs in up to 40% of patients | **[[DIC]] occurs in up to 40% of patients | ||
**FDP, d-dimer, fibrinogen, coags | **FDP, d-dimer, fibrinogen, coags | ||
*Tumor Lysis Syndrome labs | *[[Tumor Lysis Syndrome]] labs | ||
**TLS occurs in up to 10% of patients | **TLS occurs in up to 10% of patients | ||
**Chemistry | **Chemistry | ||
Line 49: | Line 50: | ||
**Interstial or alveolar infiltrates | **Interstial or alveolar infiltrates | ||
== | ==Management== | ||
*Hyperleukocytosis (asymptomatic) | *Hyperleukocytosis (asymptomatic) | ||
** | **[[Hydroxyurea]] may be all that is required | ||
*Leukostasis | *Leukostasis | ||
**IV hydration | **IV hydration | ||
Line 57: | Line 58: | ||
**Chemotherapy | **Chemotherapy | ||
***Only treatment proven to improve survival | ***Only treatment proven to improve survival | ||
**Hydroxyurea + leukapheresis | **[[Hydroxyurea]] + leukapheresis | ||
***Can be use for cytoreduction if chemo will be delayed | ***Can be use for cytoreduction if chemo will be delayed | ||
*[[Allopurinol]] may help prevent [[Tumor lysis syndrome]] | |||
*Consider [[rasburicase]] | |||
*Broad spectrum [[antibiotics]] | |||
**The leading cause of death in blast crisis is infection (patients are functionally neutropenic) | |||
==Disposition== | ==Disposition== | ||
Line 64: | Line 69: | ||
==References== | ==References== | ||
<references/> | |||
[[Category:Heme/Onc]] | [[Category:Heme/Onc]] |
Revision as of 21:28, 27 May 2019
Background
- Hyperleukocytosis is lab abnormality of WBC >50-100K
- Blood viscosity increases
- Leukostasis is symptomatic hyperleukocytosis; it is a medical emergency
- 20-40% of patients with leukostasis die within 1st week of presentation
Clinical Features
- Fever
- 80% of patients
- May be due to inflammation associated with leukostasis or concurrent infection
- Brain Leukostasis
- Pulmonary Leukostasis
Differential Diagnosis
Oncologic Emergencies
Related to Local Tumor Effects
- Malignant airway obstruction
- Bone metastases and pathologic fractures
- Malignant spinal cord compression
- Malignant Pericardial Effusion and Tamponade
- Superior vena cava syndrome
Related to Biochemical Derangement
- Hypercalcemia of malignancy
- Hyponatremia due to SIADH
- Adrenal insufficiency
- Tumor lysis syndrome
- Carcinoid syndrome
Related to Hematologic Derangement
Related to Therapy
- Chemotherapy-induced nausea and vomiting
- Cytokine release syndrome
- Chemotherapeutic drug extravasation
- Differentiation syndrome (retinoic acid syndrome) in APML
- Stem cell transplant complications
- Catheter-related complications
- Tunnel infection
- Exit site infection
- CVC obstruction (intraluminal or catheter tip thrombosis)
- Catheter-related venous thrombosis
- Fracture of catheter lumen
- Oncologic therapy related adverse events
Evaluation
Work-Up
- CBC
- DIC labs
- DIC occurs in up to 40% of patients
- FDP, d-dimer, fibrinogen, coags
- Tumor Lysis Syndrome labs
- TLS occurs in up to 10% of patients
- Chemistry
- Uric acid
- Calcium
- Phosphate
Evaluation
- High degree of suspicion needed to make the diagnosis
- WBC count usually >100K; can have symptoms with WBC as low as 50K
- CXR
- Interstial or alveolar infiltrates
Management
- Hyperleukocytosis (asymptomatic)
- Hydroxyurea may be all that is required
- Leukostasis
- IV hydration
- Prevent dehydration which can worsen condition
- Chemotherapy
- Only treatment proven to improve survival
- Hydroxyurea + leukapheresis
- Can be use for cytoreduction if chemo will be delayed
- IV hydration
- Allopurinol may help prevent Tumor lysis syndrome
- Consider rasburicase
- Broad spectrum antibiotics
- The leading cause of death in blast crisis is infection (patients are functionally neutropenic)
Disposition
- Admit to ICU